Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > Q2 earnings transcript

<< Previous

Bullboard Posts

Next >>

Comment by RazeKreationson Aug 14, 2023 7:14pm

131 Views

Post# 35588009

RE:RE:RE:RE:RE:Q2 earnings transcript

That sums it up pretty well. They may finally be on a track for substantial growth albeit it will take probably a year to see that transform into the beginnings of a stock growth run. Depending on how the FDA timelines happen. Once it starts it will continue to grow for several years. I wish i was getting in now instead of what seems to be a lifetime ago. That would have eliminated a lot of frustration. I think things look pretty good for the future.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario